Gilead’s Hepcludex (bulevirtide) Receives NICE Recommendation for the Treatment of Chronic Hepatitis Delta Virus Infection
Shots:
- NICE has recommended the use of Hepcludex as a treatment option for chronic HDV inf. on NHS use for adults with compensated liver disease in England
- Additionally, the company collaborates with Northern Ireland's health authorities to soon make bulevirtide available. The Scottish Medicines Consortium accepted bulevirtide in 2023
- In May 2023, the EMA’s CHMP adopted a positive opinion for Hepcludex recommending marketing authorization to treat adults with chronic HDV and compensated liver disease. The CHMP recommendation was based on the P-III study (MYR301) demonstrating the efficacy and safety of bulevirtide, resulting in the removal of the specific obligations after 48wks. of treatment
Ref: PharmaTimes | Image: Gilead
Related News:- Gilead Receives EMA’s CHMP Positive Opinion Recommending Marketing Authorization of Hepcludex (bulevirtide) for Hepatitis Delta Virus
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
